Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TL-895
- Development stage
- Phase 2
- Lead developer
- Telios Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TL-895 is a potent, orally available, highly selective irreversible small molecule inhibitor of Bruton's tyrosine kinase (BTK) and bone marrow tyrosine kinase X-linked (BMX). It acts by covalently binding to BTK, thereby preventing its activity and disrupting signaling pathways involved in the growth and survival of malignant B cells. TL-895 is being developed primarily for hematologic malignancies and related disorders such as myelofibrosis, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), indolent systemic mastocytosis, acute myeloid leukemia (AML), and other B-cell malignancies. The drug is administered orally in tablet or capsule form. It has demonstrated preclinical efficacy in models of B-cell lymphoma and is currently under investigation in multiple clinical trials for these indications[1][2][3][4][5][6].
- Other names
- M7583M-7583M 7583TL 895TL895TL-895
02
Targets
BLK (B lymphoid tyrosine kinase)BMX (Bone Marrow Tyrosine Kinase X-linked)BTK (Bruton tyrosine kinase)ERBB4 (Erb-b2 receptor tyrosine kinase 4)TXK
Beyond the preview
Go deeper on TL-895.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TL-895.